Side-by-side · Research reference
DihexavsLivagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED7/28 cited
BAnimal-StrongHUMAN-REVIEWED20/32 cited
Dihexa
Angiotensin IV Analogue · Pre-Clinical
Not established — animal studies only
Livagen
Khavinson Bioregulator · Hepatoprotective Tetrapeptide
Oral or SQ · Tissue-specific to liver
01Mechanism of Action
Parameter
Dihexa
Livagen
Primary target
c-Met receptor (HGF receptor tyrosine kinase)
Hepatocyte protein synthesis machineryBrodskiĭ 2001
Pathway
HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization
Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001Khavinson 2001
Downstream effect
Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models
Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes
Feedback intact?
—
—
Origin
Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015
Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)
Antibody development
—
—
02Dosage Protocols
Parameter
Dihexa
Livagen
Human dosing
Not established — no human trials
—
Animal studies
Mouse/rat models only — dosing not translatable to humans
—
Evidence basis
Pre-clinical / Rodent models
Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005Brodskiĭ 2001Khavinson 2002
Clinical status
No Phase 1, 2, or 3 trials published
—
Animal dose (oral)
—
Not specified in abstracts; 2-week administration protocolTimofeeva 2005
Per os administration in rats.
Duration (experimental)
—
2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005Brodskiĭ 2001
Route
—
Oral or subcutaneous
Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005
Human data
—
None in provided literature
04Side Effects & Safety
Parameter
Dihexa
Livagen
Human safety data
None available — no human clinical trials
No human trials in provided literature
Theoretical c-Met risks
c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile
—
Pre-clinical tolerability
Not systematically reported in available studies
—
Reported adverse effects
—
None documented in animal studies
Absolute Contraindications
Dihexa
- ·Not approved for human use — research compound only
Livagen
—Relative Contraindications
Dihexa
- ·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)
Livagen
—05Administration Protocol
Parameter
Dihexa
Livagen
1. Human administration
No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.
Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005Khavinson 2001
2. Legal status
Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.
No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005
3. Age-dependent response
—
Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005